agamod

Agamod is a pharmaceutical drug used for the treatment of generalized myasthenia gravis (GMG). It is recognized for its rapid onset of action, with clinical data showing significant improvement in MG-ADL scores within four weeks. Agamod is available in multiple dosage forms, including a prefilled subcutaneous injection approved by the FDA as of April 2025. The drug has gained wide acceptance and recommendation in GMG treatment guidelines in both the US and China, particularly among acute and refractory patient populations due to its fast-acting properties. Its mechanism of action involves targeting the neonatal Fc receptor (FcRn), which plays a role in immunoglobulin G (IgG) recycling; by inhibiting this receptor, Agamod reduces pathogenic IgG levels implicated in autoimmune diseases like GMG[5].

Brand names

agamod

Other names

agamod